Related Experiment Video

Updated: Jan 20, 2026

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
07:01

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

10.8K

Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers

J Stuart Ferriss1, M Yvette Williams-Brown2

  • 1Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, 600 N. Wolfe St, Phipps 281, Baltimore, MD, 21287, USA. jferris3@jhmi.edu.

Current Treatment Options in Oncology
|August 25, 2019
PubMed
Abstract

Insights

Research into gynecologic cancer therapies, particularly immune checkpoint inhibition, is underfunded. Further studies are needed to develop effective treatments that leverage the immune system for complete responses.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Gynecologic cancer research, especially for novel immunotherapies like immune checkpoint inhibitors, remains underfunded compared to other solid tumors.
  • Despite this, specific gynecologic cancers exhibit biological characteristics suggesting potential responsiveness to these agents.

Purpose of the Study:

  • To highlight the critical need for increased funding in gynecologic cancer research.
  • To emphasize the potential of immune checkpoint inhibition in treating these cancers.
  • To underscore the importance of understanding the tumor microenvironment for developing effective therapies.

Main Methods:

  • This study is an opinion statement based on current research trends and biological rationales.
  • It synthesizes existing knowledge on immune checkpoint inhibition and gynecologic cancers.

Main Results:

  • There is a significant gap in research and development for gynecologic cancers concerning immune checkpoint inhibitors.
  • A strong biological basis exists for exploring these therapies in common gynecologic malignancies.

Conclusions:

  • Increased research funding is essential to advance novel therapies for gynecologic cancers.
  • Further investigation into the immune system and tumor microenvironment is crucial for achieving complete treatment responses.
Keywords:
Checkpoint inhibitorsEndometrial cancerGynecologic cancersImmunotherapyLynch syndromeOvarian cancerPD-1PD-L1

More Related Videos

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery05:31

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

Published on: May 9, 2021

4.6K
Using the Chicken Chorioallantoic Membrane In Vivo Model to Study Gynecological and Urological Cancers08:13

Using the Chicken Chorioallantoic Membrane In Vivo Model to Study Gynecological and Urological Cancers

Published on: January 28, 2020

10.9K

Related Concept Videos

The Spindle Assembly Checkpoint02:19

The Spindle Assembly Checkpoint

The spindle assembly checkpoint is a molecular surveillance mechanism ensuring the fidelity of chromosome segregation during anaphase. The checkpoint monitors the completion of all the prerequisite steps before chromosome segregation to determine whether the segregation process should proceed or be delayed.
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
3.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
603
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.4K